Le Lézard
Classified in: Health, Science and technology, Business
Subjects: ERN, CCA, ACC

Alligator Bioscience AB Full Year Report 2017


STOCKHOLM, Feb. 16, 2018 /PRNewswire/ --

The Janssen collaboration continues, milestone payment of 6 MUSD triggered

Significant events, October-December

? Alligator Bioscience recorded a revenue of USD 6 million from Janssen, coupled to a decision to start combination study with ADC-1013/JNJ-64457107. This milestone payment was received in January 2018.

? A decision was taken to expand the management team with Chief Medical Officer Charlotte A Russell, MD, PhD and Vice President Discovery Peter Ellmark, Associate Professor.

? Results from Alligator Bioscience's clinical Phase I study presented, supporting a continued clinical development of ADC-1013.

? Aptevo Therapeutics and Alligator Bioscience announced the tumor antigen 5T4 as the second target for the drug candidate ALG.APV-527.

Events after the end of the period

? Theradex Oncology contracted as clinical CRO for the upcoming clinical study with ATOR-1015.

? Anudharan Balendran appointed VP Business Development starting 1 May 2018.

? Janssen clinical Phase I study with ADC-1013 ongoing.

Financial summary

October-December

? Net Sales, SEK 51.3 million (6.4).

? Operating result, SEK 10.7 million (-22.1).

? Result for the period, SEK 12.5 million (-19.4).

? Result per share, SEK 0.18 (-0.31).

? Cash, cash equivalents and bonds, SEK 547 million (659).

January-December

? Net Sales, SEK 56.9 million (58.2).

? Operating result, SEK -62.3 million (-56.1).

? Result for the period, SEK -63.8 million (-48.4).

? Result per share, SEK -0.89 (-0.80).

? Cash flow for the period before investments in bonds, SEK -108.7 million and after -183.2 (287.1).

? During the period 1,275,000 warrants (330,000) were exercised for an equivalent number of shares.

Financial summary (Group)


2017

2016

2017

2016


Oct-Dec

Oct-Dec

Jan-Dec

Jan-Dec 

 

Net sales, TSEK (SEK thousand)

 

51,299

 

6,433

 

56,875

 

58,240

 

Operating profit/loss

 

10,733

 

-22,130

 

-62,299

 

-56,081

 

Profit/loss for the period, TSEK 

 

12,516

 

-19,352

 

-63,758

 

-48,356

 

Cash flow for the period, TSEK

 

-41,694

 

310,886

 

-183,173

 

287,135

 

Cash, cash equivalents and bonds, TSEK

 

547,041

 

659,136

 

547,041

 

659,136

 

Equity ratio, %

 

96%

 

96%

 

96%

 

96%

 

R&D costs as % of operating costs excluding impairments

 

80.5%

 

68.5%

 

73.3%

 

64.3%

 

Earnings per share before dilution, SEK

 

0.18

 

-0.31

 

-0.89

 

-0.80

 

Earnings per share after dilution, SEK

 

0.18

 

-0.31

 

-0.89

 

-0.80

 

Average number of employees

 

46

 

35

 

42

 

31

Conference call

All interested parties are invited to participate in a telephone conference which will include a presentation of the Full Year Report. The event will be hosted by CEO Per Norlén and the presentation will be held in English.

When: 1:15 pm CET Friday 16 February 2018
To participate in the telephone conference, please use the dial in details shown below:
SE: +46856642664
UK: +442030089802
US: +18558315945
The presentation can also be reached at: https://tv.streamfabriken.com/alligator-bioscience-q4-2017 

The conference call will be made available on the company´s website after the call: www.alligatorbioscience.com.

The information was submitted for publication, through the agency of the contact persons set out above, at 8:00 a.m. CET on 16 February 2018.

About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's growing pipeline includes four lead clinical and preclinical drug candidates (ADC-1013, ATOR-1015, ATOR-1017 and ALG.APV-527). ADC-1013 (JNJ-64457107) is licensed to Janssen Biotech, Inc., part of J&J, for global development and commercialization. Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 50 employees. For more information, please visit www.alligatorbioscience.com.

For further information, please contact:
Per Norlén,
CEO,
[email protected],
+46-46-286-42-80.

Per-Olof Schrewelius,
CFO,
[email protected],
+46-46-286-42-85.

Cecilia Hofvander,
Director IR & Communications,
[email protected],
+46-46-286-44-95.

Alligator Bioscience AB (publ) 556597-8201
Medicon Village,
Scheelevägen 2,
223 81 Lund, Sweden.
Phone: +46-46-286-42-80.

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/alligator-bioscience/r/alligator-bioscience-ab-full-year-report-2017,c2453822

The following files are available for download:

http://mb.cision.com/Main/12681/2453822/792971.pdf

Read the complete report: Alligator Bioscience AB Full Year Report 2017

 


These press releases may also interest you

at 05:15
The "Flow Cytometry Markets. Forecasts by Technology, Product and Application. With Executive and Consultant Guides. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering. The technology is moving faster than the market. Find the...

at 05:00
The "Immunoassay Markets. Strategies and Trends. Forecasts by Application, Technology, Product, User and by Country. With Executive Guides, Customized Forecasting and Analysis. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering....

at 05:00
Medical equipment manufacturing company Aohua Endoscopy clinched the Endoscopy Product Innovation Award at the recently held Healthcare Asia Medtech Awards 2024 for its development of the Aohua 4K AQ-300 video endoscopy system, which offers an...

at 03:52
The progressive decrease in hearing in elderly people can represent a major problem for their quality of life: it has in fact been demonstrated that critical issues such as these, in addition to being a problem as such, can...

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The report titled "Central Lab Market by Service Type (Anatomic Pathology/Histology, Biomarker Services, Genetic Services), Phase (Phase 1, Phase 2, Phase 3), Therapeutic Area, End-use - Global Forecast 2024-2030" is now available on...



News published on and distributed by: